Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 7926 - 7950 of 8348 in total
Mezigdomide is under investigation in clinical trial NCT05372354 (A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma).
Investigational
Matched Description: … investigation in clinical trial NCT05372354 (A Study to Evaluate Safety, Drug Levels and Effectiveness of
Non-methylated, competitive, and irreversible inhibitor of caspase 1, as well as other caspases,1 which can be used directly with purified enzymes. It does not require an esterase to hydrolyze the O-methyl ester like the cell-permeable form, Z-Val-Ala-Asp(O-Me) fluoromethyl ketone.
Experimental
Matched Description: … Non-methylated, competitive, and irreversible inhibitor of caspase 1, as well as other caspases,1 which …
Natural killer (NK) cells can be incubated with ‘feeder cells’ expressing certain cytokines prior to maturation to enhance their activity. In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor targets that the cell is not normally sensitive to.
Investigational
Matched Description: … In particular, incubation with IL-15 allows NK cells to lyse a broad range of fresh and cultured tumor …
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile.
Investigational
Matched Description: … ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive …
Luveltamab tazevibulin, formerly known as STRO-002, is novel homogeneous folate receptor alpha (FolRα) targeting antibody-drug conjugate. It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer).
Investigational
Matched Description: … [A257414] It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate …
Litifilimab is under investigation in clinical trial NCT05531565 (A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) And/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory And/or Intolerant to Antimalarial Therapy).
Investigational
Matched Description: … Litifilimab is under investigation in clinical trial NCT05531565 (A Study to Assess the Efficacy and Safety of
Tetrahydrofolic acid is a folic acid derivative that is produced from dihydrofolic acid after conversion by dihydrofolate reductase. It is converted into 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase. It is a soluble coenzyme in many reactions, especially in the metabolism of amino acids and nucleic acids.
Nutraceutical
Matched Description: … It is a soluble coenzyme in many reactions, especially in the metabolism of amino acids and nucleic acids …
Formic acid (systematically called methanoic acid) is the simplest carboxylic acid. It is an important intermediate in chemical synthesis and occurs naturally, most famously in the venom of bee and ant stings. It is commonly used as a preservative and antibacterial agent in livestock feed.
Experimental
Investigational
Matched Description: … is an important intermediate in chemical synthesis and occurs naturally, most famously in the venom of
Matuzumab (formerly known as the experimental drug, EMD 72000) is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of blood vessels in malignancy, facilitating tumor growth and survival.
Investigational
Matched Description: … a high affinity for EGFR (epithelial growth factor receptor), frequently associated with the growth of
SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen.
Investigational
Matched Description: … SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. …
AZD-8330 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival. AZD-8330 has shown tumor suppressive activity in multiple preclinical models of human cancer including melanoma, pancreatic, colon, lung, and breast cancers.
Investigational
Matched Description: … AZD-8330 has shown tumor suppressive activity in multiple preclinical models of human cancer including …
Apatorsen is a second generation antisense drug which in preclinical experiments, inhibits production of Heat Shock Protein 27 (Hsp27) a cell survival protein found at elevated levels in many human cancers including prostate, lung, breast, ovarian, bladder, renal, pancreatic, multiple myeloma and liver cancer.
Investigational
Matched Description: … Apatorsen is a second generation antisense drug which in preclinical experiments, inhibits production of
Highly potent and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of the NMDA receptor-channel complex (Kd = 0.8 nM). Gavestinel displays > 1000-fold selectivity over NMDA, AMPA and kainate binding sites and is orally bioavailable and active in vivo.
Investigational
Matched Description: … and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of
N-methylnicotinamide is an experimental drug with no approved indication or marketed formulation. It is a metabolite of niacinamide/nicotinamide and niacin/nicotinic acid (vitamin B3), and as such N-methylnicotinamide is used to diagnose niacin deficiency by measuring N-methylnicotinamide in the urine.
Experimental
Matched Description: … It is a metabolite of niacinamide/nicotinamide and niacin/nicotinic acid (vitamin B3), and as such N-methylnicotinamide …
Ammonium molybdate is a source of molybdenum that exists in several hydrate forms. It is intravenously administered as an additive to solutions for Total Parenteral Nutrition (TPN). Molybdenum is an essential element that is present in enzymes including xanthine oxidase, sulfite oxidase, and aldehyde oxidase.
Experimental
Matched Description: … Ammonium molybdate is a source of molybdenum that exists in several hydrate forms. …
Cardamonin (also known as Dihydroxymethoxychalcone), as shown by the increasing number of publications, has received growing attention from the scientific community due to the expectations toward its benefits to human health. Cardamonin's name comes from the fact that it can be found in cardamom spice.
Experimental
Matched Description: … Cardamonin (also known as Dihydroxymethoxychalcone), as shown by the increasing number of publications …
Cetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers).
Investigational
Matched Description: … NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of
AVI-7537 is an antisense molecule that binds to the Ebola virus mRNA to prevent the viral replication. AVI-7537 is under investigation in clinical trial NCT01593072 (A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers).
Investigational
Matched Description: … investigation in clinical trial NCT01593072 (A Study to Assess the Safety, Tolerability and Pharmacokinetics of
AEM-28-14 is an analog of AEM-28, an apolipoprotein E mimetic peptide, with a 400 percent greater cholesterol-lowering efficacy and a several-fold increase in drug tolerability. It is being investigated for lipid disorders such as homozygous familial hypercholesterolemia.
Investigational
Matched Description: … AEM-28-14 is an analog of [AEM-28], an apolipoprotein E mimetic peptide, with a 400 percent greater cholesterol-lowering …
SX-682 is under investigation in clinical trial NCT04574583 (Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With Bintrafusp Alfa (M7824 or Tgf-beta "Trap"/pd-l1) With CV301 TRICOM in Advanced Solid Tumors (STAT)).
Investigational
Matched Description: … Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of
A pteridine derivative present in body fluids; elevated levels result from immune system activation, malignant disease, allograft rejection, and viral infections. (From Stedman, 26th ed) Neopterin also serves as a precursor in the biosynthesis of biopterin.
Experimental
Matched Description: … (From Stedman, 26th ed) Neopterin also serves as a precursor in the biosynthesis of biopterin. …
Latrunculin A is an actin binding macrolide purified from the red sea sponge Latrunculia magnifica. It is under investigation for the treatment of cancer. It disrupts actin polymerization, prevents mitotic spindle formation and thus cell replication.
Experimental
Matched Description: … It is under investigation for the treatment of cancer. …
Torcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination of atorvastatin and the study drug.
Investigational
Matched Description: … 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination of
Nanoparticle Epirubicin is under investigation in clinical trial NCT03168061 (Dose-escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma). It is a novel epirubicin drug-conjugated polymeric micelle.
Investigational
Matched Description: … Epirubicin is under investigation in clinical trial NCT03168061 (Dose-escalation and Expansion Trial of
ZB131 is a monoclonal antibody with a high affinity and specificity for cancer-specific plectin (CSP), a cell surface protein identified in a wide range of cancers that correlates with poor prognosis and aggressive tumors.
Investigational
Matched Description: … and specificity for cancer-specific plectin (CSP), a cell surface protein identified in a wide range of
Displaying drugs 7926 - 7950 of 8348 in total